Improving Outcomes in Anaplastic Lymphocyte Kinase-Positive Metastatic Non-Small Cell Lung Cancer
Cancer Therapy Advisor,
By Clinical Content Hub Among cancer types, lung cancer is the most frequently diagnosed, having accounted for 11.4% of the…
By Clinical Content Hub Among cancer types, lung cancer is the most frequently diagnosed, having accounted for 11.4% of the…
ALK TKIs have proven efficacy in the frontline treatment of patients with advanced, ALK -positive non–small cell lung cancer (NSC…
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with…
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with…